Affimed (NASDAQ:AFMD) Stock Crosses Below 50-Day Moving Average of $5.54

Affimed (NASDAQ:AFMD)’s stock price crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $5.54 and traded as low as $4.72. Affimed shares last traded at $5.00, with a volume of 95,885 shares traded.

Analyst Ratings Changes

AFMD has been the subject of several research analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a research note on Monday, April 1st. HC Wainwright upped their target price on Affimed to $10.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. Wells Fargo & Company decreased their target price on Affimed from $30.00 to $25.00 and set an “overweight” rating for the company in a research report on Monday, April 1st. Finally, StockNews.com assumed coverage on Affimed in a report on Tuesday, January 2nd. They issued a “sell” rating for the company. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $45.00.

Affimed Trading Down 2.9 %

The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.23 and a current ratio of 3.25. The business has a fifty day simple moving average of $5.54 and a 200 day simple moving average of $5.01. The company has a market cap of $76.15 million, a P/E ratio of -0.60 and a beta of 2.05.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Vestal Point Capital LP bought a new position in Affimed during the 4th quarter worth approximately $341,000. BNP Paribas Financial Markets lifted its holdings in Affimed by 39.9% during the 4th quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock worth $357,000 after buying an additional 163,162 shares during the last quarter. EWA LLC acquired a new stake in shares of Affimed during the 4th quarter worth approximately $89,000. Finally, abrdn plc acquired a new stake in shares of Affimed during the 4th quarter worth approximately $130,000. Institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.